KalVista Pharmaceuticals (KALV) Other Accumulated Expenses (2016 - 2025)

KalVista Pharmaceuticals has disclosed Other Accumulated Expenses across 10 years of filings, most recently posting $681000.0 for Q3 2025.

• Other Accumulated Expenses for Q3 2025 came in at $681000.0, down 48.17% year-over-year; the trailing twelve-month figure through Jul 2025 was $681000.0 (down 48.17% YoY), and the FY2025 annual result was $806000.0, up 218.58% from the prior year.
• Other Accumulated Expenses came in at $681000.0 for Q3 2025 at KalVista Pharmaceuticals, down from $806000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q3 2024 to a low of $124000.0 in Q1 2021.
• The 5-year median for Other Accumulated Expenses is $253000.0 (2024), against an average of $365000.0.
• Across the five-year window, Other Accumulated Expenses slumped 55.4% in 2021 and jumped 787.84% in 2024, its largest moves.
• KalVista Pharmaceuticals' Other Accumulated Expenses stood at $190000.0 in 2021, then increased by 17.89% to $224000.0 in 2022, then jumped by 40.18% to $314000.0 in 2023, then soared by 120.7% to $693000.0 in 2024, then dropped by 1.73% to $681000.0 in 2025.
• The last three Other Accumulated Expenses figures came in at $681000.0 (Q3 2025), $806000.0 (Q2 2025), and $693000.0 (Q4 2024), per Business Quant data.